Paliperidone Palmitate Depot in the Long-term Treatment of Psychotic Bipolar Disorder: A Case Series

Clin Neuropharmacol. 2015 Sep-Oct;38(5):209-11. doi: 10.1097/WNF.0000000000000103.

Abstract

Objectives: The treatment of bipolar disorder (BD) cannot be limited to the remission of acute phases but includes the long-term treatment in order to prevent relapses, poor outcome, and chronicity. The purpose of this article is to present 3 cases of severe psychotic bipolar patients treated with monthly injection of paliperidone pamoate.

Methods: Three poor-compliant severe psychotic BD patients were initiated to paliperidone palmitate (100-150 mg monthly), and they were followed up for 12 months. Young Mania Rating Scale and Hamilton Depression Rating Scale were administered at baseline and during monthly follow-up visits.

Results: None of patients presented recurrences or relapses during the 12-month follow-up period. The patients did not develop adverse effects or significant changes in metabolism.

Conclusions: These preliminary results indicate that paliperidone palmitate (100-150 mg monthly) may be a therapeutic option for long-term treatment of psychotic BD, particularly for poor-compliant severe patients. These results have to be confirmed in double-blind studies with bipolar patients not necessarily belonging to psychotic subtype.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use
  • Bipolar Disorder / drug therapy*
  • Delayed-Action Preparations / administration & dosage
  • Female
  • Humans
  • Male
  • Middle Aged
  • Paliperidone Palmitate / administration & dosage
  • Paliperidone Palmitate / therapeutic use*

Substances

  • Antipsychotic Agents
  • Delayed-Action Preparations
  • Paliperidone Palmitate